Life Sciences Tools and Services

JOINN

Insys Intelligence and ZhaoYan New Drug Sign Strategic Cooperation Agreement

JOINN released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 316.14 M, actual EPS CNY 0.32 (forecast EPS CNY 0.06)

JOINN to Release FY2026 Q1 Earnings on April 29 After-Market (BJT), Forecast EPS CNY 0.06

Zhaoyan New Drug Reports 2025 Net Profit Increase of 302.08%

JOINN released FY2025 annual earnings on March 30 After-Market (BJT), actual revenue CNY 1.658 B (forecast CNY 1.598 B), actual EPS CNY 0.4 (forecast CNY 0.3375)

JOINN released FY2025 Q4 earnings on March 30 After-Market (BJT), actual revenue CNY 672.66 M (forecast CNY 717.23 M), actual EPS CNY 0 (forecast CNY 0.3)

JOINN to Release FY2025 Earnings on March 30 After-Market (BJT), Forecast Revenue CNY 1.598 B, EPS CNY 0.3375

Share Price Pressure on Zhaoyan New Drug Following Major Shareholder's Complete Exit

Zhaoyan Pharmaceutical Shareholders Adjust 减持 Plan

Shareholders of Shouyao New Drug Plan to Reduce Holdings

ZY Therapeutics' Controlling Shareholder Zhou Zhiwen Terminates 减持 Plan Prematurely

Zhaoyan New Drug's Controlling Shareholder Zhou Zhiwen Reduces Shareholding

Zhaoyan New Drug's Net Profit Soars Due to Rhesus Monkey Price Surge

Zhaoyan New Drug's Net Profit Forecast to Increase by 214-371% in 2025

Controlling Shareholder of Chiome Pharmaceutical Plans to Reduce Shares

Multiple Executives of ZhaoYan New Drug Completed their Stock Sale Plans

Director Sun Yunxia of Zhaoyan New Drug Reduces 100,000 Shares

Directors of Zhaoyan New Drug Reduced Shares

Huaxi Securities Maintains '增持' Rating for Zhaoyan Pharmaceutical, Predicts Future Demand Improvement

Executives of Syneos Health China Cut Shares Held

603127

06127

JOINN Laboratories (China) Co., Ltd. has granted 1,430,000 H-share awards to 12 selected participants, representing 1.20% of its issued H shares. The awards, priced at nil, will vest over three years based on performance indicators. This initiative aims to align management with shareholders and enhance long-term performance. The current analyst rating for JOINN Laboratories (HK:6127) is a Hold, with a price target of HK$16.30. The company specializes in preclinical research services and has a market cap of HK$30.67B.

Tip Ranks

JOINN Laboratories Grants New Three-Year H-Share Awards to Management

516930

516500

159849

159837

Today, JOINN's transaction volume was approximately HKD 67 million. Although the absolute volume is not large, the emergence of bullish signals on the daily MACD level has attracted technical attention. The crossover pattern of the DIF line and the DEA line usually indicates that recent selling pressure is waning, and the market has formed a certain degree of balance between buying and selling at the current price level. As a representative enterprise in the domestic preclinical CRO field, JOINN has accumulated a significant decline since its previous high, and the current bullish signal appears at a relatively low level, exhibiting certain characteristics of "oversold recovery." On the news front, the preclinical CRO industry is in a transitional period of capacity digestion and order structure adjustment. The R&D investment of domestic innovative pharmaceutical companies continues to grow, but intensified industry competition has put pressure on unit prices, and JOINN still faces a complex operating environment. On the macro level, the Federal Reserve remains on hold but has not changed its hawkish stance, which may slow the valuation recovery process of the global biopharmaceutical sector. However, the Hong Kong stock market showed a generally warm performance today, with multiple sectors of the Hang Seng Index rising, boosting sentiment for small and mid-cap pharmaceutical stocks. From a technical perspective, JOINN's transaction volume of HKD 67 million is still within a normal range for its daily trading, but it remains insufficient to support a substantial rebound. Bullish signals require sustained volume support to translate into actual price breakthroughs. Recently, attention should be paid to the overall capital flow in the CXO sector and whether there are new orders or performance catalysts at the company level

Technical Forecast

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

Hang Seng Index

Pre-market trend | JOINN (6127.HK) showed buying signals at a low on April 29, has the rebound window opened?

601600

515030

159306

00HSI

36Kr learned that the Hang Seng Index opened up 0.27%, and the Hang Seng Tech Index rose 0.08%; the pharmaceutical and biotechnology, automotive, and non-ferrous metal sectors led the gains, with JOINN and BAIC MOTOR rising over 3%, CHALCO rising over 2%, and Nio rising over 1%; the semiconductor, building materials, and hardware equipment sectors weakened, with Zhaoyi Innovation falling over 4%, HESAI falling over 3%, and ACC falling over 1%

36Kr

CHALCO

Hua Xia CSI New Energy Vehicles ETF

Ping An CSI Auto Components Thematic ETF

China Southern CSI SWS Non-Ferrous Metal ETF

Penghua Guozheng Non-ferrous Metal Industry ETF

HESAI-W

Fidelity Electric Vehicles and Future Transportation ETF

ChinaAMC CSI Hong Kong Connect Automobile Industry Thematic ETF

GX HS TECH

Guotai CSI Non-Ferrous Metal Kuangye Theme ETF

Yinhua CSI Non-ferrous Metal ETF

HSTECH ETF

HFT CSI Auto Components Thematic ETF

Hwabao WP CSI Non-ferrous Metal ETF

ChinaAMC CSI Auto Components Thematic ETF

CSOP HS TECH

Hang Seng TECH Index

Hwabao WP CSI Intelligent Electric Vehicle ETF

Guotai CSI Non-ferrous Metal ETF

BAIC MOTOR

Guotai CSI 800 Automobile and Parts ETF

E Fund CSI Auto Components Thematic ETF

CAM HS TECH

GF CSI Rare Metals Theme ETF

ISHARESHSTECH

ChinaAMC CSI Subdivision Non-ferrous Metal Sub-Industry ETF

The Hang Seng Index opened up 0.27%, and the Hang Seng TECH Index rose 0.08%

JOINN announced its 2025 annual performance, with revenue of 1.658 billion RMB (same below), a year-on-year decrease of 17.9%. It recorded a net profit of 298 million RMB, an increase of 302.1%, with earnings per share of 0.40 RMB. The final dividend is 0.12 RMB, compared to 0.03 RMB in the same period last year

AASTOCKS

First Trust NYSE Arca Biotech Index Fd

JOINN's annual net profit is 298 million RMB, a threefold increase, with a final dividend of 12 cents

513120

01801

The Hong Kong innovative drug sector continued to rise in the afternoon, with JOINN and CSPC PHARMA up over 10%, INNOVENT BIO up over 7%, and JUNSHI BIO and INNOCARE following suit

Wallstreetcn

GF CSI HK Innovative Drugs Industry ETF(QDII)

INNOVENT BIO

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

CSPC PHARMA

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

China Universal CNI HK Connect Innovative Drugs Industry ETF

InnoCare Pharma

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Huaan Hang Seng Biotech ETF

JUNSHI BIO

Guotai CSI Hugangshen Innovative Drugs Industry ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

INNOCARE

JOINN: Shareholders Gu Xiaolei and Gu Meifang plan to adjust the total reduction ratio from no more than 4.1026% of the company's total share capital to 3.00%, while changing the reduction method from centralized bidding to a combination of centralized bidding and block trading

36Kr learned that the Hang Seng Index closed down 2.14%, and the Hang Seng Technology Index fell 2.89%; the semiconductor, retail, and pharmaceutical biotechnology sectors led the decline, with Tianzu Zhixin down over 10%, JOINN down over 7%, and Meituan and Alibaba down over 4%; the oil and petrochemical, non-ferrous metals, and coal sectors saw the largest gains, with Shandong Molong up over 115%, SD-GOLD up over 7%, and China Coal Energy up over 3%; southbound funds had a net purchase of HKD 16.214 billion

SD-GOLD

CSOP HSI ETF

ISHARESHSI-R

ChinaAMC Hang Seng ETF

Huatai-PB CSOP Hang Seng Technology ETF(QDII)

KraneShares 2x Long BABA Daily ETF

ChinaAMC Hang Seng Technology ETF(QDII)

Guotai CES Semiconductor Chip Industry ETF

BABA 2x Long Daily ETF - GraniteShares

ISHARESHSI-U

Krne Csi China Internet

XI2CSOPHSTECH

Hang Seng TECH ETF I

GTJA Allianz SSE STAR Chip Design Thematic ETF

Tianhong Hang Seng TECH ETF(QDII)

Meituan

MEITUAN

BABA-W

The Hang Seng Index closed down 2.14%, and the Hang Seng Technology Index fell 2.89%

JOINN(603127.SH)